Entheon Announces Termination of Mentis AI Agreement
Rhea-AI Summary
Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) has announced that Mentis AI (1000141080 Ontario ) has terminated the letter of intent (LOI) dated January 23, 2025. The LOI had outlined the terms for Entheon's proposed acquisition of all issued and outstanding common shares of Mentis AI. This termination follows the company's previous news release dated January 24, 2025.
Positive
- None.
Negative
- Failed acquisition attempt of Mentis AI
- Termination of strategic growth opportunity
News Market Reaction
On the day this news was published, ENTBF gained 15.54%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Vancouver, British Columbia--(Newsfile Corp. - March 14, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that, further to its news release dated January 24, 2025, 1000141080 Ontario Ltd. ("Mentis AI") has terminated the letter of intent ("LOI") dated January 23, 2025 which set out the terms whereby Entheon would acquire all of the issued and outstanding common shares in the capital of Mentis AI.
About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.
On Behalf of the Board of Directors,
Timothy Ko, CEO, President and Director
For more information, please contact the Company at:
Entheon Biomedical Corp.
Timothy Ko, CEO
1 (604) 562-3932
timothy@entheonbiomedical.com
https://entheonbiomedical.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244657
FAQ
What happened to the Entheon Biomedical (ENTBF) and Mentis AI merger agreement?
When was the Entheon Biomedical (ENTBF) and Mentis AI LOI originally announced?
What was the scope of the terminated Entheon (ENTBF) acquisition deal?
Which stock exchanges is Entheon Biomedical listed on?
